Skip to main content

A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naive myelofibrosis and moderate thrombocytopenia

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Karyopharm Therapeutics

Start Date

August 1, 2024

End Date

July 31, 2029
 

Administered By

Duke Cancer Institute

Awarded By

Karyopharm Therapeutics

Start Date

August 1, 2024

End Date

July 31, 2029